Kazia Therapeutics Limited
KZIA
$10.05
-$0.39-3.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.24% | 1.95% | -- | -- | -- |
| Total Other Revenue | 895.17% | 993.18% | 21,350.00% | 20,133.33% | 18,883.33% |
| Total Revenue | -28.97% | 71.43% | 274,583.33% | 273,366.67% | 272,116.67% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -28.97% | 71.43% | 274,583.33% | 273,366.67% | 272,116.67% |
| SG&A Expenses | -36.38% | 1.36% | 58.09% | 57.12% | 54.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.71% | -6.07% | 60.61% | 41.86% | 25.08% |
| Operating Income | 50.43% | 10.08% | -47.85% | -30.55% | -15.04% |
| Income Before Tax | 18.27% | -17.92% | -78.49% | -50.80% | -27.38% |
| Income Tax Expenses | -524.93% | -258.55% | 0.78% | 1.00% | 2.58% |
| Earnings from Continuing Operations | 23.76% | -14.84% | -79.86% | -51.58% | -27.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.76% | -14.84% | -79.86% | -51.58% | -27.77% |
| EBIT | 50.43% | 10.08% | -47.85% | -30.55% | -15.04% |
| EBITDA | 52.47% | 10.19% | -53.02% | -33.51% | -16.52% |
| EPS Basic | 60.19% | 24.17% | -27.75% | 3.53% | 21.91% |
| Normalized Basic EPS | 65.74% | 32.18% | -7.07% | 15.60% | 30.20% |
| EPS Diluted | 60.18% | 24.17% | -27.75% | 3.53% | 21.91% |
| Normalized Diluted EPS | 65.74% | 32.18% | -7.07% | 15.60% | 30.20% |
| Average Basic Shares Outstanding | 107.80% | 82.67% | 54.03% | 49.18% | 43.09% |
| Average Diluted Shares Outstanding | 115.00% | 91.89% | 64.71% | 60.00% | 53.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |